Search clinical trials for: Cetuximab (Erbitux)

Total 1033 results

Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Sharp & Dohme LLC; Pivotal S.L.

Terminated

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy (EXTAX)

Head and Neck Cancer
Weill Medical College of Cornell University

Terminated

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Glioblastoma Multiforme | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Brain Stem Glioma | Pilomyxoid Astrocytoma | Glioma of Brainstem | Fibrillary Astrocytoma of Brain | Mixed Oligodendroglioma-Astrocytoma

United States
Northwell Health

Completed

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

GBM | Anaplastic Astrocytoma | Glioblastoma Multiforme (GBM) | ANAPLASTIC ASTROCYTOMA (AOA)

United States
US Oncology Research
Eli Lilly and Company; Sanofi

Completed

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Gastric Cancer Adenocarcinoma Metastatic

United States
University of Heidelberg Medical Center
iOMEDICO AG

Completed

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) (HICARE)

Head and Neck Cancer

Germany
Sorlandet Hospital HF
Merck KGaA, Darmstadt, Germany; Frontier Science & Technology Research Foundation...

Completed

Novel Treatment Option for Neuropathic Pain (NoTOPain)

Neuralgia | Complex Regional Pain Syndromes

Norway
Heinrich-Heine University, Duesseldorf

Completed

Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (ACCRA-HN)

Head and Neck Cancer

Germany
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
Georgetown University

Terminated

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Head and Neck Squamous Cell Cancer

United States
P.O. Witteveen
Merck KGaA, Darmstadt, Germany

Terminated

Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma (TRACC)

Resectable Esophageal Cancer

Netherlands
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype (MUTEX)

Colorectal Neoplasms

Spain
Eli Lilly and Company

Completed

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Advanced Cancer

Puerto Rico, United States
Merck KGaA, Darmstadt, Germany

Completed

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Head and Neck Cancer

Korea, Republic of
Karolinska University Hospital

Unknown

Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET)

Squamous Cell Carcinoma of the Head and Neck

Denmark, Sweden
Eli Lilly and Company
Bristol-Myers Squibb

Completed

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

Colorectal Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Lecia V. Sequist
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical... and other collaborators

Terminated

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Non-small Cell Lung Cancer

United States
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
David A. Clump, MD, PhD

Completed

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
ISU Abxis Co., Ltd.

Active, not recruiting

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Solid Tumor

Korea, Republic of
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Massachusetts General Hospital; Beth Israel Deaconess Medical...

Completed

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

Neoplasm Metastasis | Gastric Cancer | Esophageal Cancer

United States
Merck KGaA, Darmstadt, Germany

Withdrawn

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Neoplasms, Squamous Cell
ARCAGY/ GINECO GROUP

Terminated

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix (ERBUS)

Cervix Cancer

France
Eli Lilly and Company
Bristol-Myers Squibb

Terminated

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Ovarian Cancer

United States
University of Maryland, Baltimore
Bristol-Myers Squibb

Completed

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

Cancer of Head and Neck

United States
University of California, Irvine

Terminated

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

Head and Neck Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
University of Pittsburgh
Bristol-Myers Squibb

Completed

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Non Small Cell Lung Cancer (NSCLC)

United States
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
Cinnagen

Recruiting

Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Iran, Islamic Republic of
Eli Lilly and Company

Completed

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

Mucinous Gastrointestinal Adenocarcinoma

United States
Institute of Oncology Ljubljana

Unknown

Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer (XERT)

Rectal Cancer

Slovenia
University of Cincinnati

Completed

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR); American Cancer...

Completed

Cetuximab in Head and Neck Cancer Patients

Head and Neck Cancer | Squamous Cell Carcinoma

United States
University of Zurich

Completed

A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab

Laryngeal Cancer | Hypopharyngeal Cancer | Oropharyngeal Cancer

Switzerland
University Hospital, Ghent
Merck Sharp & Dohme LLC

Completed

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (MesoMab)

Cancer

Belgium, Netherlands
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (2007-01)

HNSCC

France
Carmen Schade-Brittinger

Completed

Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer (ATIP)

Adenocarcinoma

Germany
Ruijin Hospital
Henan Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaborators

Unknown

Cetuximab Monotherapy Maintenance Treatment in mCRC

Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy

Lung Cancer
University of California, Davis
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
West China Hospital

Recruiting

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

China
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (NEOPECS)

Locally Advanced Cutaneous Squamous Cell Carcinoma
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (BERING-CRC)

Metastatic Colorectal Carcinoma

Austria, Germany

Search clinical trials for: Cetuximab (Erbitux)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations